Physician profile
Andrew Sun
NPI 1497744619
$2,334.52
in general payments reported to CMS, 2019-2025
29 companies · $165 in 2025
The $165 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $351 · 2020: $101 · 2021: $904 · 2022: $439 · 2023: $283 · 2024: $91.97 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $539.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celularity INC. | $600.00 | 2021 | |
| Abbvie INC. | $276.38 | 2019-2023 | Liletta |
| Momentis Surgical INC. | $183.00 | 2022 | |
| Exeltis, USA INC. | $155.61 | 2019-2023 | Slynd |
| Coopersurgical, INC. | $132.77 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Boston Scientific Corporation | $123.90 | 2019 | |
| Medtronic, INC. | $84.61 | 2021-2023 | Truclear |
| Daiichi Sankyo INC. | $81.52 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $80.14 | 2021-2025 | |
| Evofem Biosciences, INC. | $77.28 | 2021-2025 | Phexxi, Solosec, Phexx |
| Sage Therapeutics, LLC | $71.32 | 2024-2025 | Zurzuvae |
| Therapeuticsmd, INC. | $52.94 | 2019-2022 | |
| Millicent US INC | $41.66 | 2019-2025 | Intrarosa |
| Astellas Pharma US INC | $41.01 | 2025 | Veozah |
| Lupin INC. | $39.86 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $32.43 | 2021 | |
| Sumitomo Pharma America, INC. | $30.39 | 2023 | Gemtesa |
| Vertical Pharmaceuticals, LLC | $28.55 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $27.35 | 2023 | Inpefa |
| Allergan, INC. | $26.75 | 2019-2020 | |
| Exact Sciences Corporation | $24.22 | 2025 | Cologuard Collection Kit |
| Organon LLC | $24.16 | 2024 | |
| Roche Diagnostics Corporation | $19.59 | 2021 | |
| Ferring Pharmaceuticals INC. | $17.10 | 2023 | Rebyota |
| Hologic Sales and Service, LLC | $17.07 | 2020 | |
| Scynexis, INC. | $16.66 | 2022 | |
| Amag Pharmaceuticals, INC. | $14.64 | 2019 | |
| Avion Pharmaceuticals | $13.61 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Sun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.